Glaxo Wins U.S. Approval to Sell Breo Only to Adults With Asthma
This article is for subscribers only.
GlaxoSmithKline Plc and Theravance Inc.’s respiratory drug Breo Ellipta won U.S. approval to expand its use to treat asthma, though only for patients 18 and older.
The Food and Drug Administration cleared the inhaled medicine, according to a statement from the companies.